Forced Vital Capacity

Between a group of carpenters and an age-, sex- and height-matched group of university employees, carpenters had worse average lung function values, according to results published in BMC Pulmonary Medicine.

Around 20% to 25% of individuals with rapidly declining FEV1/FVC trajectories experienced wheezing and usual phlegm/bronchitis as adolescents/young adults, according to results published in The Lancet Respiratory Medicine.

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according to FIBRONEER-ILD topline results.

In a set of healthy school-aged children, several lung function measures, including FEV1 and FVC, improved with classroom plus bedroom air purification, according to results published in JAMA Pediatrics.

Patients with idiopathic pulmonary fibrosis had less FVC decline between baseline and 26 weeks with receipt of three daily doses of 825 mg deupirfenidone, according to phase 2b ELEVATE IPF trial results.

Patients with idiopathic pulmonary fibrosis had improved FVC between baseline and 12 weeks with receipt of ISM001-055, a small molecule targeting Traf2- and Nck-interacting kinase, vs. placebo, according to topline results.

Among school-age children, residence near more green spaces in early childhood positively impacted lung function, according to results published in Environment International.

Adults with idiopathic pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according to FIBRONEER-IPF topline results.

With just chest X-rays, an AI model estimated FVC and FEV1 and had “excellent agreement” when compared with spirometry results, according to results published in The Lancet Digital Health.

SAN DIEGO — Taking an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks slowed time to disease progression in idiopathic pulmonary fibrosis, according to a presentation at the American Thoracic Society International Conference.